ValiRx plc (VAL.L)

3.4500 0.0000 (0.00%) At close: 03:35PM BST

ValiRx plc

Eliot Park Innovation Centre
4 Barling Way
Nuneaton CV10 7RH
United Kingdom
44 24 7679 6496
https://www.valirx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 8

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D.	CEO & Director	160.85k	N/A	1978
Mr. James Gerry Desler FCA	CFO, Company Secretary & Executive Director	53k	N/A	1945
Mr. Kumar Nawani	Head of Operations	N/A	N/A	N/A
Dr. Catherine Jane Tralau-Stewart Ph.D.	Chief Scientific Officer & Board Observer	N/A	N/A	N/A
Mr. Tarquin Edwards	Head of Investor Relations & Communications	N/A	N/A	N/A
Mr. Mark Treharne	Corporate Development Manager	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.

Corporate governance

ValiRx plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.